Amir Landi

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Abdolamir Landi)
Amir Landi.png

Abdolamir Landi, MD, PhD, also known as, Amir Landi, is a senior research scientist and principal investigator in the Department of Medical Microbiology and Immunology at the University of Alberta, Canada. He serves as a member of the ME/CFS committee of the Alberta Medical Association and a Research and Medical Advisor to National ME/FM Action Network, Canada. He has been working on the immunologic aspects of ME/CFS since 2010.[1]

Dr. Landi leads the biomarker team in Professor Michael Houghton's laboratory in the Department of Medical Microbiology and Immunology at the University of Alberta, Canada, working to validate a panel of cytokine biomarkers for ME/CFS.[2]

Dr. Landi is a scientific member of the executive committee and the chair of the working group Infection & Immunity of Interdisciplinary Canadian Collaborative ME (ICanCME) Research Network.

Education[edit | edit source]

  • 1995, MD - Tehran University of Medical Sciences, Iran[3]
  • 2009, PhD - Immunovirology / Vaccinology from University of Saskatchewan, Canada[3]
  • 2010, post-doctorate fellowship - Vaccine and Infectious Disease Organization, International Vaccine Centre, Saskatoon, Saskatchewan, Canada[3]
  • 2015, post-doctorate fellowship - University of Alberta, Edmonton, Alberta, Canada

Clinical care guidelines[edit | edit source]

  • 2016, Toward Optimized Practice (TOP) ME/CFS Clinical Practice Guidelines[4]

Patents[edit | edit source]

  • 2019, Methods and compositions in diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis. US Patent: 10,408,844The patent is for two assay algorithms of specific cytokines and chemokines for a serologic diagnostic test for CFS/ME. Inventors: Abdolamir Landi, David Broadhurst,D. Lorne J. Tyrrell, Michael Houghton[5]

Research studies[edit | edit source]

  • 2011, No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome[6] - (Full text)
  • 2016, Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome[7] - (Full text)

Talks and interviews[edit | edit source]

  • 27-30 May 2015, Biomedical Research into ME Colloquium (BRMEC5), London, UK - Speech title: Cytokine and Chemokine Profiles of ME/CFS Patients.
  • 3-5 May 2018, ME/CFS Canadian Collaborative Team Conference, Montreal, Canada - Speech title: Diagnosis of ME/CFS: Can Immune Modulators Play a Role?[8]
  • 14 & 15 Dec. 2018, CIHR ME/CFS Strengthening Workshop, Montreal, Canada - Speech title: Immunobiology of ME/CFS: From pathogen discovery to pathogenesis.
  • 24 October 2019, Canadian CBC Radio, Morning Episodes
  • 28 October 2019, Canadian Global NEWS Edmonton TV interview: Global News, Health Matters

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved March 6, 2019.
  2. "What's the Buzz - September". Bateman Horne Center. September 23, 2016. Retrieved March 31, 2019.
  3. 3.0 3.1 3.2 "Amir Landi". LinkedIn. Retrieved March 31, 2019.
  4. "Myalgic Encephalomyelitis/Chronic Fatigue Syn - Toward Optimized Practice (TOP) - CPGs". topalbertadoctors.org. Retrieved August 27, 2019.
  5. "Michael Houghton Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved November 6, 2019.
  6. Steffen, Imke; Tyrrell, D. Lorne; Stein, Eleanor; Montalvo, Leilani; Lee, Tzong-Hae; Zhou, Yanchen; Lu, Kai; Switzer, William M.; Tang, Shaohua; Jia, Hongwei; Hockman, Darren; Santer, Deanna M.; Logan, Michael; Landi, Amir; Law, John; Houghton, Michael; Simmons, Graham (November 17, 2011). "No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian Patients with Chronic Fatigue Syndrome". PLoS ONE. 6 (11): e27870. doi:10.1371/journal.pone.0027870. ISSN 1932-6203. PMC 3219700. PMID 22114717.
  7. Landi, Abdolamir; Broadhurst, David; Vernon, Suzanne D.; Tyrrell, D. Lorne J.; Houghton, Michael (February 2016). "Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome". Cytokine. 78: 27–36. doi:10.1016/j.cyto.2015.11.018.
  8. "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved March 6, 2019.